Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

A. Bardia, W. A. Messersmith, E. A. Kio, J. D. Berlin, L. Vahdat, G. A. Masters, R. Moroose, A. D. Santin, K. Kalinsky, V. Picozzi, J. O'Shaughnessy, J. E. Gray, T. Komiya, J. M. Lang, J. C. Chang, A. Starodub, D. M. Goldenberg, R. M. Sharkey, P. Maliakal, Q. HongW. A. Wegener, T. Goswami, A. J. Ocean

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Background: Sacituzumab govitecan (SG), a trophoblast cell surface antigen-2 (Trop-2)-directed antibody-drug conjugate, has demonstrated antitumor efficacy and acceptable tolerability in a phase I/II multicenter trial (NCT01631552) in patients with advanced epithelial cancers. This report summarizes the safety data from the overall safety population (OSP) and efficacy data, including additional disease cohorts not published previously. Patients and methods: Patients with refractory metastatic epithelial cancers received intravenous SG (8, 10, 12, or 18 mg/kg) on days 1 and 8 of 21-day cycles until disease progression or unacceptable toxicity. Endpoints for the OSP included safety and pharmacokinetic parameters with investigator-evaluated objective response rate (ORR per RECIST 1.1), duration of response, clinical benefit rate, progression-free survival, and overall survival evaluated for cohorts (n > 10 patients) of small-cell lung, colorectal, esophageal, endometrial, pancreatic ductal adenocarcinoma, and castrate-resistant prostate cancer. Results: In the OSP (n = 495, median age 61 years, 68% female; UGT1A1∗28 homozygous, n = 46; 9.3%), 41 (8.3%) permanently discontinued treatment due to adverse events (AEs). Most common treatment-related AEs were nausea (62.6%), diarrhea (56.2%), fatigue (48.3%), alopecia (40.4%), and neutropenia (57.8%). Most common treatment-related serious AEs (n = 75; 15.2%) were febrile neutropenia (4.0%) and diarrhea (2.8%). Grade ≥3 neutropenia and febrile neutropenia occurred in 42.4% and 5.3% of patients, respectively. Neutropenia (all grades) was numerically more frequent in UGT1A1∗28 homozygotes (28/46; 60.9%) than heterozygotes (69/180; 38.3%) or UGT1A1∗1 wild type (59/177; 33.3%). There was one treatment-related death due to an AE of aspiration pneumonia. Partial responses were seen in endometrial cancer (4/18, 22.2% ORR) and small-cell lung cancer (11/62, 17.7% ORR), and one castrate-resistant prostate cancer patient had a complete response (n = 1/11; 9.1% ORR). Conclusions: SG demonstrated a toxicity profile consistent with previous published reports. Efficacy was seen in several cancer cohorts, which validates Trop-2 as a broad target in solid tumors.

Original languageEnglish (US)
Pages (from-to)746-756
Number of pages11
JournalAnnals of Oncology
Volume32
Issue number6
DOIs
StatePublished - Jun 2021

Keywords

  • IMMU-132
  • SN-38
  • Trop-2
  • antibody-drug conjugate
  • colorectal cancer
  • endometrial cancer
  • small-cell lung cancer
  • Humans
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Antibodies, Monoclonal, Humanized
  • Immunoconjugates
  • Female
  • Camptothecin/analogs & derivatives

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial'. Together they form a unique fingerprint.

Cite this